Partnering
Partnering with Unguard Therapeutics
Advancing next-generation precision oncology together.
We collaborate with pharmaceutical companies, biotech partners, and academic institutions to accelerate the development of innovative therapies targeting HRD cancers.
Why partner with us
A differentiated scientific platform
Our approach is built on a novel synthetic lethality mechanism targeting uracil misincorporation and DNA repair vulnerabilities.
Strong scientific foundation
• Institut Curie origin
• validated biological rationale
• robust preclinical data
Partnership opportunities
We are actively exploring:
• Co-development partnerships
• Strategic collaborations in translational research
• Licensing opportunities
• Combination strategies with existing therapies
Areas of interest
• HRD cancers (ovarian, breast, prostate, pancreatic)
• PARPi-resistant populations
• Combination therapies
• DNA repair targeting strategies
Our partners
The Curie Institute is a public-interest foundation created in 1921 by Marie Curie and other scientists and philanthropists. Its mission is based on three pillars: research, care, and knowledge sharing. It conducts fundamental, translational, and clinical research in fields such as physics, chemistry, biology, and radiobiology, with a focus on understanding and treating diseases, especially cancer. It also provides diagnosis, follow-up, and treatment through its hospital network in Paris, Orsay, and Saint-Cloud, affiliated with Unicancer.
The Institute of Women’s Cancers places women at the center of research and innovation, aiming to reduce the incidence and mortality of breast and gynecological cancers while improving the patient experience. Co-founded by Institut Curie, PSL University, and Inserm, it is a University Hospital Institute (IHU) and part of the France 2030 excellence initiative. It is based on the idea that treating these cancers requires moving beyond a tumor-centered approach.
MATWIN (Maturation & Accelerating Translation With Industry) is a French open-innovation platform specifically dedicated to oncology. A subsidiary of the Unicancer group (which brings together the 18 French Comprehensive Cancer Centers), MATWIN has been offering various initiatives (expertise, accelerator program, events, etc.) for over 15 years aimed at accelerating the development of innovative projects dedicated to the fight against cancer.
Neighborhood provides personalized mentoring, the expertise of VCLS, and a broad network to unlock startups’ global regulatory strategy, derisk their product development and build their community. Neighborhood has a proven track-record of making projects more financeable, thanks to our unique expertise built through close collaboration with regulators and our expansive network of industry actors. Neighborhood boosts startups bringing innovative products to patients.